Iran becomes second country in the world to establish tilmanocept production

Iran has successfully synthesised of Technetium (99mTc) tilmanocept, a radiopharmaceutical imaging agent used to detect lymph nodes affected by tumours. This is reported by Tehran Times, a partner of TV BRICS.

This scientific advancement makes Iran the second country in the world to develop this vital diagnostic tool.

Accurate identification of affected lymph nodes is crucial for surgeons, as failure to do so often results in the removal of extensive sections of the lymphatic system, leading to severe complications, including immune system suppression and circulatory issues.

With the introduction of this cutting-edge radiodiagnostic agent, surgeons can now pinpoint affected lymph nodes with precision, minimising unnecessary surgeries and significantly reducing risks for patients.

This breakthrough is expected to improve cancer diagnostics and treatment accessibility for nearly 90 per cent of patients in Iran, offering a more cost-effective and accurate solution.

The newly developed agent has successfully completed preclinical trials and has now advanced to the clinical testing phase.

Iran has also made significant progress in the production of ibrutinib, a crucial drug for treating blood cancers. In September 2023, Iranian researchers became the third in the world, alongside India and China, to develop this high-tech medication and its raw materials, reinforcing Iran’s growing influence in the global pharmaceutical industry.

Photo: iStock